| EMPA-REG | TECOS | SAVOR-TIMI | SUSTAIN-6 | LEADER | EXSCEL | REWIND | PIONEER-6 | DECLARE |
---|---|---|---|---|---|---|---|---|---|
Duration of diabetes | Â | X | X | X | X | X | X | Â | X |
Age | X | X | X | X | X | X | X | X | X |
Sex | X | X | X | X | X | X | X | X | Â |
HbA1c | X | X | X | X | X | X | X | X | Â |
BMI | X | X | X | X | X | X | X | X | Â |
Body weight | Â | Â | X | Â | Â | Â | Â | Â | Â |
Systolic blood pressure | X | X | Â | Â | Â | Â | Â | Â | Â |
Diastolic blood pressure | X | X | Â | Â | Â | Â | Â | Â | Â |
Established CVD | X | Â | Â | X | X | X | X | X | Â |
Prior MI or Stroke | X | Â | Â | X | Â | Â | X | X | Â |
PAD | X | Â | Â | Â | Â | Â | Â | Â | Â |
Previous MI | X | Â | Â | Â | Â | Â | Â | Â | X |
Heart failure | Â | X | X | X | X | X | Â | Â | X |
CVD risk factors | X | Â | Â | X | X | Â | Â | X | X |
Only cerebrovascular disease | X | Â | Â | Â | Â | Â | Â | Â | Â |
eGFR | X | X | Â | X | X | X | Â | X | X |
Urinary albumin/creatinine ratio | X | Â | X | Â | Â | Â | Â | Â | Â |
Anti-diabetic therapy | Â | Â | Â | Â | X | Â | Â | Â | Â |
Insulin | X | X | X | X | Â | X | Â | Â | Â |
Metfromin | X | X | X | Â | Â | Â | Â | Â | Â |
Sulphonylurea | X | X | X | Â | Â | Â | Â | Â | Â |
Thiazolidinediones | X | X | X | Â | Â | Â | Â | Â | Â |
DPP-4i | X | Â | Â | Â | Â | X | Â | Â | Â |
Anti-hypertive therapy | X | Â | X | Â | Â | Â | Â | Â | Â |
RAS blockers | Â | X | X | Â | Â | Â | Â | Â | Â |
Calcium channel blockers | X | X | Â | Â | Â | Â | Â | Â | Â |
Beta blockers | X | X | Â | Â | Â | Â | Â | Â | Â |
Diuretics | X | X | X | Â | Â | Â | Â | Â | Â |
Aspirin | X | Â | Â | Â | Â | Â | Â | Â | Â |
Statin | X | X | X | Â | Â | Â | Â | Â | Â |
Europe | X | X | X | X | X | X | X | Â | Â |
Ethnicity | X | Â | Â | X | X | Â | Â | Â | Â |
White | X | X | X | X | X | X | X | X | Â |
Number of variables | 28 | 20 | 18 | 14 | 13 | 12 | 9 | 9 | 6 |